We study the biology and the diseases of red blood cells, which are the most abundant cell in the human body. And not only are they a source of disease during infections like malaria, but also they are themselves a … Read More
Megan Mazzei from McNamara lab has been Awarded a Mini-grant and a Travel Award to go to the Netherlands from the Leducq Transatlantic Network of Excellence Entitled “Checkpoint Athero”. Congratulations Megan!!
Brett Ransegnola from McNamara Lab Received his Notice of Award for his F30 Proposal, “Molecular Regulators of Marginal Zone B Cells in Atherosclerosis”. Congratulations Brett!!
Arthritis drugs already available for prescription have the potential to halt lingering lung problems that can last months or years after COVID-19 infections, new research from the School of Medicine and Cedars-Sinai suggests. By examining damaged human lungs and developing … Read More
The Tibor Greenwalt Memorial Award from the AABB (Association for the Advancement of Blood and Biotherapies), recognizes an individual who made major scientific or clinical contributions to hematology, transfusion medicine or biotherapies, and succinctly communicated these advances. In recognition of … Read More
Dr. Loren Erickson and Dr. Coleen McNamara receive their 3rd supplement for $200,000 total per year for 3 years on their NIH R01. The research project seeks to understand the effects of IgE to alpha-gal on atherosclerotic plaque development and … Read More
New School of Medicine research led by Lian-Wang Guo, PhD, a professor of surgery; Craig Kent, MD, chief executive officer of UVA Health, executive vice president for health affairs, and professor of surgery; and Coleen McNamara, MD, a professor of … Read More
University of Virginia School of Medicine researchers have identified a potential treatment for the respiratory symptoms of long COVID after discovering an unknown cause of the condition inside the lungs. The UVA researchers, led by Jie Sun, PhD, found that … Read More
This research focuses on understanding how certain immune responses can lead to chronic lung conditions after viral pneumonia, like COVID-19. We and others identified a novel immune cell population, the CD4+ tissue-resident T cells, which stays in the lungs and … Read More
Vasarya Therapeutics, Inc., was awarded an NIH STTR (Small Business Technology Transfer) with Dr. Young Hahn to validate a novel therapeutic approach for liver fibrosis treatment. Liver fibrosis represents a significant financial burden on the U.S. health system, and to … Read More
